Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 431-435

  Yano, Tokujiro ^a   Okamoto, Tatsuro ^b   Haro, Akira ^b   Fukuyama, Seiichi ^a   Yoshida, Tsukihisa ^b   Kohno, Mikihiro ^b   Maehara, Yoshihiko ^b  

^a NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Local therapy; Non small cell lung cancer; Oligometastases; Postoperative recurrence; Progression free survival

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; GEFITINIB; PLATINUM DERIVATIVE;

ADRENAL GLAND; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; LOCAL THERAPY; LUNG NON SMALL CELL CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMETASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOFT TISSUE;

LOCAL THERAPY; NON-SMALL CELL LUNG CANCER; OLIGOMETASTASES; POSTOPERATIVE RECURRENCE; PROGRESSION-FREE SURVIVAL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84887611683     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.006     Document Type: Article

References (27)

1. Goya T., Asamura H., Yoshimura H., Kato H., Shimokata K., Tsuchiya R., et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005, 50:227-234.
2. Yano T., Morodomi Y., Ito K., Yoshida T., Haro A., Shoji F., et al. Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancer-special reference to tumor size. J Thorac Oncol 2010, 5:45-48.
3. Ichinose Y., Yano T., Yokoyama H., Inoue T., Asoh H., Tayama K., et al. Postrecurrent survival of patients with non-small-cell lung cancer undergoing a complete resection. J Thorac Cardiovasc Surg 1994, 108:158-161.
4. Williams B.A., Sugimura H., Endo C., Nichols F.C., Cassivi S.D., Allen M.S., et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 2006, 81:1021-1027.
5. Sugimura H., Nichols F.C., Yang P., Allen M.S., Cassivi S.D., Deschamps C., et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007, 83:409-417.
6. Yano T., Hara N., Ichinose Y., Asoh H., Yokoyama H., Ohta M., et al. Local recurrence after complete resection for non-small cell carcinoma of the lung: Significance of local control by radiation treatment. J Thorac Cardiovasc Surg 1994, 107:8-12.
7. MacDermed D.M., Weichselbaum R.R., Salama J.K. A rational for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 2008, 98:202-206.
8. Hishida T., Nagai K., Yoshida J., Nishimura M., Ishii G., Iwasaki M., et al. Is surgical resection indicated for a solitary non-small cell lung cancer recurrence. J Thorac Cardiovasc Surg 2006, 131:838-842.
9. Yano T., Haro A., Yoshida T., Morodomi Y., Ito K., Shikada Y., et al. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. J Surg Oncol 2010, 102:852-855.
10. Martini N., Melamed M.R. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975, 70:606-612.
11. Antakli T., Schaefer R.F., Rutherford B.S., Read R.C. Second primary lung cancer. Ann Thorac Surg 1995, 59:863-867.
12. Yano T., Yokoyama H., Inoue T., Asoh H., Tayama K., Takai E., et al. The first site of recurrence after complete resection in non-small-cell carcinoma of the lung. J Thorac Cardiovasc Surg 1994, 108:680-683.
13. Yano T., Yokoyama H., Inoue T., Asoh H., Tayama K., Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level; lobar or hilar nodes. J Thorac Cardiovasc Surg 1994, 107:1398-1402.
14. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-909.
15. Hellman S., Weichselbaum R.R. Oligometastatic disease at presentation and recurrence for nonsmall cell lung cancer. J Clin Oncol 1995, 13:8-10.
16. Gomez D.R., Niibe Y., Chang J. Oligometastatic disease at presentation and recurrence for nonsmall cell lung cancer. Pulm Med 2012, 10.1155/2012/396592.
17. Okawara G., Mackay J.A., Evans W.K., Ung Y.C. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 2006, 1:377-393. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.
18. Ruysscher D.D., Wanders R., Baardwijk A., Dingemans A.M., Reymen B., Houben R., et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases. Long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 2012, 7:1547-1555.
19. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
20. Paz-Ares L., de Marinis F., Dediu M., Thomas M., Pujol J.L., Bidoli P., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012, 13:247-255.
21. Mariya Y., Sekizawa G., Matsuoka Y., Seki H., Sugawara T. Outcome of sterotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain. J Radiat Res 2010, 51:333-342.
22. Tanvetyanon T., Robinson L.A., Schell M.J., Strong V.E., Kapoor R., Coit D.G., et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008, 26:1142-1147.
23. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
24. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
25. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
26. Weickhardt A.J., Scheier B., Burke J.M., Gan G., Lu X., Bunn P.A., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012, 7:1807-1814.
27. Yu H.A., Sima C.S., Huang J., Solomon S.B., Rimner A., Paik P., et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013, 8:346-351.